Therapeutic effect of ribbon-type nuclear factor-κB decoy oligonucleotides in a rat model of inflammatory bowel disease

Current Gene Therapy

Volumn 12, Issue 6, 2012, Pages 484-492

  Ozaki, Kazunari ^a   Makino, Hirofumi ^a   Aoki, Motokuni ^b   Miyake, Takashi ^a   Yasumasa, Natsuki ^a,c   Osako, Mariana Kiomy ^a,c   Nakagami, Hironori ^c   Rakugi, Hiromi ^a   Morishita, Ryuichi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MORINOMIYA UNIVERSITY OF MEDICAL SCIENCES   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

Drug development; Gene therapy; Inflammation; Transcription factor

Indexed keywords

DOUBLE STRANDED PHOSPHOROTHIOATED DECOY OLIGONUCLEOTIDE; FLUORESCEIN ISOTHIOCYANATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; OLIGONUCLEOTIDE; PERFLUTREN; RIBBON TYPE NUCLEAR FACTOR KAPPA B DECOY OLIGONUCLEOTIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; COLITIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSFECTION; IMMUNOFLUORESCENCE; MALE; NONHUMAN; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE;

ANIMALS; BODY WEIGHT; COLON; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCENT ANTIBODY TECHNIQUE; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTESTINAL MUCOSA; MALE; NF-KAPPA B; OLIGODEOXYRIBONUCLEOTIDES; ORGAN SIZE; RATS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TIME FACTORS; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

RATTUS;

EID: 84870192275     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/156652312803519814     Document Type: Article

References (40)

1. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003; 3: 521-33.
2. Uhlig HH, Powrie F. Dendritic cells and the intestinal bacterial flora: a role for localized mucosal immune responses. J Clin Invest 2003; 112: 648-51.
3. Targan SR. Current limitations of IBD treatment: where do we go from here? Ann N Y Acad Sci 2006; 1072: 1-8.
4. Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, et al. Antiinterleukin- 12 antibody for active Crohn's disease. N Engl J Med 2004; 351: 2069-2079.
5. Becker C, Wirtz S, Blessing M, Pirhonen J, Strand D, et al. Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells. J Clin Invest 2003; 112: 693-706.
6. Hue S, Ahern P, Buonocore S, Kullberg MC, Cua DJ, et al. Interleukin- 23 drives innate and T cell-mediated intestinal inflammation. J Exp Med 2006; 203: 2473-2483.
7. Baeuerle PA, Baltimore D. NF-kappa B: ten years after. Cell 1996; 87: 13-20.
8. Baldwin AS, Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996; 14: 649-83.
9. Berman KS, Verma UN, Harburg G, Minna JD, Cobb MH, et al. Sulindac enhances tumor necrosis factor-alpha-mediated apoptosis of lung cancer cell lines by inhibition of nuclear factor-kappaB. Clin Cancer Res 2002; 8: 354-60.
10. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 1994; 265: 956-59.
11. Wahl C, Liptay S, Adler G, Schmid RM. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 1998; 101: 1163-1174.
12. Kawamura I, Morishita R, Tsujimoto S, Manda T, Tomoi M, et al. Intravenous injection of oligodeoxynucleotides to the NF-kappaB binding site inhibits hepatic metastasis of M5076 reticulosarcoma in mice. Gene Ther 2001; 8: 905-12.
13. Miyake T, Aoki M, Nakashima H, Kawasaki T, Oishi M, et al. Prevention of abdominal aortic aneurysms by simultaneous inhibition of NFkappaB and ets using chimeric decoy oligonucleotides in a rabbit model. Gene Ther 2006; 13: 695-704.
14. Nakashima H, Aoki M, Miyake T, Kawasaki T, Iwai M, et al. Inhibition of experimental abdominal aortic aneurysm in the rat by use of decoy oligodeoxynucleotides suppressing activity of nuclear factor kappaB and ets transcription factors. Circulation 2004; 109: 132-38.
15. Ono S, Date I, Onoda K, Shiota T, Ohmoto T, et al. Decoy administration of NF-kappaB into the subarachnoid space for cerebral angiopathy. Hum Gene Ther 1998; 9: 1003-1011.
16. Tomita N, Morishita R, Tomita S, Kaneda Y, Higaki J, et al. Inhibition of TNF-alpha, induced cytokine and adhesion molecule. Expression in glomerular cells in vitro and in vivo by transcription factor decoy for NFkappaB. Exp Nephrol 2001; 9: 181-90.
17. Yamasaki K, Asai T, Shimizu M, Aoki M, Hashiya N, et al. Inhibition of NFkappaB activation using cis-element 'decoy' of NFkappaB binding site reduces neointimal formation in porcine ballooninjured coronary artery model. Gene Ther 2003; 10: 356-364.
18. Yoshimura S, Morishita R, Hayashi K, Yamamoto K, Nakagami H, et al. Inhibition of intimal hyperplasia after balloon injury in rat carotid artery model using cis-element 'decoy' of nuclear factorkappaB binding site as a novel molecular strategy. Gene Ther 2001; 8: 1635-1642.
19. Eckstein F. Phosphorothioate analogues of nucleotides-Tools for the investigation of biochemical processes. Angew Chem Int Ed Engl 1983; 22: 423-39.
20. Miller PS, McParland KB, Jayaraman K, Ts'o PO. Biochemical and biological effects of nonionic nucleic acid methylphosphonates. Biochemistry 1981; 20: 1874-1880.
21. Kume M, Komori K, Matsumoto T, Onohara T, Takeuchi K, et al. Administration of a decoy against the activator protein-1 binding site suppresses neointimal thickening in rabbit balloon-injured arteries. Circulation 2002; 105: 1226-1232.
22. Morishita R, Gibbons GH, Horiuchi M, Ellison KE, Nakama M, et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci U S A 1995; 92: 5855-5859.
23. Morishita R, Sugimoto T, Aoki M, Kida I, Tomita N, et al. In vivo transfection of cis element decoy against nuclear factor-kappaB binding site prevents myocardial infarction. Nat Med 1997; 3: 894-99.
24. Fichtner-Feigl S, Fuss IJ, Preiss JC, Strober W, Kitani A. Treatment of murine Th1- and Th2-mediated inflammatory bowel disease with NF-kappa B decoy oligonucleotides. J Clin Invest 2005; 115: 3057-71.
25. Xiang JY, Wu LG, Huang XL, Zhang M, Pen L, et al. Amelioration of murine dextran sulfate sodium-induced colitis by nuclear factor-kappaB decoy oligonucleotides. Am J Surg 2009; 197: 797-805.
26. Brown DA, Kang SH, Gryaznov SM, DeDionisio L, Heidenreich O, et al. Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J Biol Chem 1994; 269: 26801-26805.
27. Burgess TL, Fisher EF, Ross SL, Bready JV, Qian YX, et al. The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc Natl Acad Sci U S A 1995; 92: 4051-55.
28. Gao WY, Han FS, Storm C, Egan W, Cheng YC. Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology. Mol Pharmacol 1992; 41: 223-29.
29. Hosoya T, Takeuchi H, Kanesaka Y, Yamakawa H, Miyano- Kurosaki N, et al. Sequence-specific inhibition of a transcription factor by circular dumbbell DNA oligonucleotides. FEBS Lett 1999; 461: 136-40.
30. Osako MK, Tomita N, Nakagami H, Kunugiza Y, Yoshino M, et al. Increase in nuclease resistance and incorporation of NF-kappaB decoy oligodeoxynucleotides by modification of the 3'-terminus. J Gene Med 2007; 9: 812-19.
31. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, et al. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993; 75: 253-61.
32. Taurog JD, Richardson JA, Croft JT, Simmons WA, Zhou M, et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994; 180: 2359-64.
33. Mayer L, Eisenhardt D, Salomon P, Bauer W, Plous R, et al. Expression of class II molecules on intestinal epithelial cells in humans. Differences between normal and inflammatory bowel disease. Gastroenterology 1991; 100: 3-12.
34. Gibson I. Antisense approaches to the gene therapy of cancer-- 'Recnac'. Cancer Metastasis Rev 1996; 15: 287-99.
35. Taniyama Y, Tachibana K, Hiraoka K, Namba T, Yamasaki K, et al. Local delivery of plasmid DNA into rat carotid artery using ultrasound. Circulation 2002; 105: 1233-39.
36. Cooper HS, Murthy SN, Shah RS, Sedergran DJ.Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993; 69: 238-49.
37. Murthy SN, Cooper HS, Shim H, Shah RS, Ibrahim SA, et al. Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Dig Dis Sci 1993; 38: 1722-34.
38. Tas SW, Vervoordeldonk MJ, Tak PP. Gene therapy targeting nuclear factor-kappaB: towards clinical application in inflammatory diseases and cancer. Curr Gene Ther 2009; 9: 160-170.
39. Buttaro C, Fruehauf JH. Engineered E. coli as vehicles for targeted therapeutics. Curr Gene Ther 2010; 10: 27-33.
40. Tong H, Qin S, Fernandes JC, Li L, Dai K, Zhang X. Progress and prospects of chitosan and its derivatives as non-viral gene vectors in gene therapy. Curr Gene Ther 2009; 9: 495-502.